进博会现场：数据+AI解决方案 构建创新药多元支付智能生态

Core Insights - The 8th China International Import Expo (CIIE) held from November 5 to 10 in Shanghai continues to amplify its spillover effects, serving as a crucial platform for showcasing cutting-edge technologies and products to Chinese consumers while linking global innovation with domestic market demands [1][2] Group 1: Industry Developments - The pharmaceutical multi-payment platform, Meixin Health, launched its AI + Data Intelligent Hub platform, mind42.ai, at the CIIE, with partnerships from major pharmaceutical companies like AstraZeneca, Bristol-Myers Squibb, Pfizer China, Roche, and Zai Lab [1] - China's innovative drug industry has seen rapid development with increasing R&D investments and successful overseas launches of original new drugs, yet faces challenges in commercialization due to a single payment system [1][2] Group 2: Policy and Payment Mechanisms - The Chinese government is actively promoting a multi-tiered medical security system, introducing policies such as the "Several Measures to Support the High-Quality Development of Innovative Drugs," which includes the establishment of a commercial health insurance directory for innovative drugs [2] - The transition to a multi-payment mechanism is expected to enhance the accessibility of innovative drugs for patients, with a focus on breaking traditional boundaries between pharmaceuticals and insurance through AI applications and infrastructure improvements [2][3] Group 3: Future Outlook - Industry leaders express optimism about the role of AI in reshaping the entire pharmaceutical R&D and production chain, aiming to make quality medical resources more accessible and safeguard the health of millions of families in China [3]